Definium Therapeutics, Inc. (DFTX) Stock Score, Valuation & Financial Research

Definium Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DFTX

Definium Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 35.62. These figures are a research snapshot, not a buy or sell recommendation.

What Definium Therapeutics, Inc. does

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Definium Therapeutics is a late-stage clinical biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel product candidates to treat brain health disorders, relying on capital raises and financing activities to fund its clinical trials and operations.

Products and services

  • The company is developing a pipeline of therapeutic candidates for psychiatric and neurological disorders, including DT120 ODT for generalized anxiety disorder.

Customer types

Patients with brain health disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various third-party contract research organizations to conduct its clinical trials and research activities; specific supplier names are unnamed. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are unnamed. Source

Business strengths to evaluate

  • Scientific leadership in psychedelic-based psychiatric research Source
  • Strong cash position to fund clinical development Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source

Sources: Company research source · Strong cash position to fund clinical development

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DFTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 35.62
Market capitalization:
4.73B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -353.79M
Free cash flow:
USD -131.56M
Cash:
USD 655.27M
Total debt:
USD 36.47M
EPS:
USD -3.44

What stands out

  • Free cash flow is USD -131.56M, negative for the stored period.
  • The balance sheet shows USD 655.27M of cash versus USD 36.47M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 618.8M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DFTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DFTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DFTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DFTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DFTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DFTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.